Close Menu

NEW YORK (GenomeWeb) – Veracyte reported after the close of the market on Tuesday that its first quarter 2019 revenues grew 47 percent year over year.

For the three months ended March 31, the genomic testing firm reported total revenues of $29.5 million, compared to $20.0 million in Q1 2018, beating analysts' average estimate of $27.6 million.

In addition, the firm's testing volumes grew by 33 percent year over year, to 9,162 tests.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.